Results 191 to 200 of about 65,496 (283)
A Review of Current Computational Tools for Peptide–Protein Docking
In this review, we compare 14 specialized peptide‐protein docking programs, adaptable small‐molecule docking tools, and emerging AI‐driven approaches. By clarifying how each method works, we offer researchers an accessible guide to selecting the most suitable tools for biochemical studies and peptide‐focused drug discovery.
Fábio G. Martins +2 more
wiley +1 more source
The Caenorhabditis elegans DPF‐3 and human DPP4 have tripeptidyl peptidase activity
The dipeptidyl peptidase IV (DPPIV) family comprises serine proteases classically defined by their ability to remove dipeptides from the N‐termini of substrates, a feature that gave the family its name. Here, we report the discovery of a previously unrecognized tripeptidyl peptidase activity in DPPIV family members from two different species.
Aditya Trivedi, Rajani Kanth Gudipati
wiley +1 more source
A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor. [PDF]
Fukata M +5 more
europepmc +1 more source
Abstract INTRODUCTION The aim of this study was to investigate the cognitive and cerebrovascular outcomes of patients with hypertension (HTN) receiving various renin‐angiotensin system (RAS) inhibitors. METHODS We further categorized 39,665 patients with HTN receiving long‐term RAS inhibitor therapy into (1) telmisartan, (2) non‐telmisartan angiotensin
Chi‐Hung Liu +5 more
wiley +1 more source
ABSTRACT The impressive growth in the global market for plant‐based foods has a direct impact on the food industry, requiring greater efforts in product reformulation for the replacement of animal‐based ingredients, including proteins. The replacement of animal‐derived proteins frequently applied as emulsifiers in food formulations, for example ...
Thais C. Brito‐Oliveira +2 more
wiley +1 more source
Association of urinary dipeptidyl peptidase 4 activity with clinical outcomes in people with chronic kidney disease. [PDF]
Benetti A +7 more
europepmc +1 more source
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman +13 more
wiley +1 more source
Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. [PDF]
Prakash V, Goel N.
europepmc +1 more source
ABSTRACT Background Previous studies reported an inverse association between diabetes and prostate cancer. Moreover, the associations of smoking with breast and prostate cancers remain inconclusive. This study aims to investigate whether diabetes, smoking, or metabolic factors are associated with female breast and prostate cancers incidence, and ...
Sarah Tsz Yui Yau +4 more
wiley +1 more source
DPPPRED-IV: An Ensembled QSAR-Based Web Server for the Prediction of Dipeptidyl Peptidase 4 Inhibitors. [PDF]
Carpio LE +5 more
europepmc +1 more source

